A Double- Blind, Randomized, Placebo and Active Controlled, Multi-Center Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-Estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes.

Trial Profile

A Double- Blind, Randomized, Placebo and Active Controlled, Multi-Center Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-Estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2015

At a glance

  • Drugs ZK 283197 (Primary) ; Estradiol
  • Indications Hot flashes
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 01 Sep 2012 Planned number of patients changed from 112 to 118.
    • 05 Feb 2009 Actual patient numbers (112) added as reported by ClinicalTrials.gov.
    • 05 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top